Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

This study tests an intensive combination treatment — using daratumumab and carfilzomib together with other drugs, followed by a stem cell transplant — in people with newly diagnosed ultra high-risk multiple myeloma. Ultra high-risk myeloma includes tumors with multiple dangerous genetic changes, cancer growing outside the bone marrow, or cancer cells circulating in the blood. **You may be eligible if...** - You are between 18 and 70 years old - You have newly diagnosed multiple myeloma with ultra high-risk features: either two or more high-risk genetic changes, cancer growing outside the bone marrow, or leukemia-like spread of plasma cells in the blood - You have not received any prior systemic myeloma treatment (prior bisphosphonates and localized radiation are okay) - You are fit enough for intensive chemotherapy and a stem cell transplant - Your overall health is good (ECOG 0 or 1) **You may NOT be eligible if...** - You have already received systemic myeloma treatment - You are not healthy enough for a stem cell transplant - You do not have ultra high-risk features as defined by the study Talk to your doctor to see if this trial is right for you.